

## **Transplant ID Guidance on Measles Prevention for UCSF HBC Group**

Last updated 3/31/25

### **VACCINATION**

- For patients with hematologic malignancy without evidence of measles immunity\* and without contraindication†, administer MMR vaccine series
  - \*Evidence of immunity (at least one)
    - Born before 1957
    - Documentation of age-appropriate vaccination with 1-2 doses of a live measles virus-containing vaccine
      - Poor protection from inactivated vaccine in use 1963-1976
    - Laboratory confirmation of disease
    - Laboratory evidence of measles immunity
      - Check measles IgG if patient would be eligible for vaccine
  - †Contraindications to MMR vaccination
    - HCT recipients
      - <12 months from auto-HCT
      - <24 months from allo-HCT
      - On immunosuppression and/or with GVHD
    - CAR-T recipients
      - <12 months from CAR-T
      - CAR-T recipient on immunosuppression and/or with GVHD
    - Less than 4 weeks before or 3 months after completion of immunosuppressive chemotherapy
    - Receipt of IVIG within 8-11 months
- Caregivers / household contacts of immunocompromised patients should be assessed for immunity and vaccinated as appropriate

### **POST-EXPOSURE PROPHYLAXIS**

- **Measles exposure definition**: sharing the same airspace with a confirmed measles case during their infectious period
  - Infectious period: four days before rash onset through four days after rash onset
  - Time period of exposure: up to 1 hour after the infectious person has left (applies even if the infectious person was masked)
- **Immunoglobulin** post-exposure prophylaxis should be administered **within 6 days** of measles exposure to the below
  - Regardless of prior evidence of immunity\*
    - HCT recipients <24 months from transplant (allo or auto), on immunosuppression and/or with GVHD
    - CAR-T recipients within <12 months from CAR-T, on immunosuppression, and/or not in remission
    - Heme malignancy patients <6 months from completion of immunosuppressive chemotherapy
  - Without evidence of measles immunity and >3 days and <6 days from exposure
  - Agents
    - IVIG 400mg/kg (adequate protection if received equivalent dose within 3 weeks of exposure)
    - SCIG 0.5mL/mg (adequate protection if received equivalent dose within 2 weeks of exposure)
- **MMR vaccine** post-exposure prophylaxis **within 3 days** of measles exposure is an option for populations not meeting indication for immunoglobulin prophylaxis and without contraindication to MMR